Navigation Links
Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 16, 2009
Date:11/10/2009

BASKING RIDGE, N.J., Nov. 10 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Ellen McDonald, MBA, Senior Vice President and Chief Business Officer, will be presenting at Biotech 2009 held at the Pennsylvania Convention Center in Philadelphia, Pennsylvania. Ms. McDonald's presentation will be given at 10:15am (EST) on Monday, November 16 and will include an overview of the Company's pipeline with emphasis on the lead development program, the anticoagulant system, REG1. In its ninth year, this annual joint symposium of BioNJ and Pennsylvania Bio is designed to advance the growth and development of the bioscience industry in this geographic region.

ABOUT REGADO BIOSCIENCES

Regado Biosciences is pioneering a new therapeutic technology with the creation and development of two-component drug systems. Each system comprises a nuclease-stabilized RNA aptamer that can be controlled directly by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics, including anticoagulants and antiplatelet agents, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control. Regado's technology is designed to give physicians the ability to actively and directly control each system's therapeutic effect providing a safe and unique approach to personalized medicine.

ABOUT REG1 and REG2

Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents both administered by IV bolus, the first being a potent highly selective Factor IXa inhibitor (RB006) and the second being its complementary active control agent (RB007). RB007 can be used to selectively completely or partially reverse the anticoagulant effect of RB006. REG1, presently in phase 2b clinical trial, is intended for application in arterial thrombosis applications, initially in Acute Coronary Syndrome patients undergoing Percutaneous Coronary Intervention. REG2, Regado's second product candidate, consists of a subcutaneously administered formulation of RB006 paired with the IV bolus formulation of RB007. REG2 is currently undergoing phase 1 clinical testing and is intended for use in venous thrombosis indications

ABOUT APTAMERS

RB006 is a member of a class of compounds called aptamers. Aptamers are single stranded oligonucleotides that adopt a specific conformation enabling direct, specific inhibition of the targeted protein. A key unique feature of aptamers derives from the fact that they are formed from nucleic acids. As such, their pharmacologic activity can be controlled by a matched, complementary oligonucleotide active control agent (the Watson-Crick base pair complement of a fraction of the agent to be controlled), which can bind to the aptamer, removing it from its target and reversing it biologic effects.

More information can be found at http://www.regadobio.com.

SOURCE Regado Biosciences


'/>"/>
SOURCE Regado Biosciences
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Regado Biosciences To Present at the 2009 Japan Biopharma Partnering Conference on October 6, 2009
2. Regado Biosciences Announces Allowance in Europe of a Fundamental Patent Broadly Covering Oligonucleotide Modulators to Blood Coagulation Factor Aptamers
3. Regado Biosciences to Present at the BioPharm America 2009 Conference on September 17, 2009
4. Regado Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2009 on September 11, 2009
5. Regado Biosciences to Present at the Rodman & Renshaw Global Investment Conference on September 10, 2009
6. Regado Biosciences Announces First Patient Enrolled In Phase 1 Study Of Subcutaneously Administered Reg1 Anticoagulation System
7. Regado Biosciences Expands Medical Advisory Board
8. Regado Biosciences Establishes Medical Advisory Board
9. Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer
10. Regado Biosciences To Present at the 27th Annual J.P. Morgan Healthcare Conference
11. Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... , April 25, 2017 ... has licensed its novel immune-modulating technology to an undisclosed ... and allergy. Tregitopes, pronounced T·rej·itopes, are ... immunoglobulin by EpiVax CEO Annie De Groot ... intravenous immunoglobulin G, an autoimmune disease therapy, Tregitopes ...
(Date:4/24/2017)... ... 24, 2017 , ... It is well established that ligand ... broad application of this cellular target engagement concept to drug discovery has been ... stabilization assays are valuable methods for particular applications, but they can require target-specific ...
(Date:4/21/2017)... ... 2017 , ... The University of Connecticut, in partnership with ... startups through the UConn Innovation Fund. The $1.5 million UConn Innovation Fund was ... , The UConn Innovation Fund provides investments of up to $100,000 to companies ...
(Date:4/21/2017)... ... April 21, 2017 , ... Frederick Innovative ... range of emerging technology-based businesses, recently earned a $77,518 grant from the Rural ... Founded in 2004, FITCI is Frederick’s first incubator. A non-profit corporation, FITCI is ...
Breaking Biology Technology:
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/29/2017)...  higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... - Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle ... around 15.1% over the next decade to reach approximately $1,580 million ... estimates and forecasts for all the given segments on global as ...
Breaking Biology News(10 mins):